Vyzulta®
Latanoprostene Bunod 0.024% · ophthalmic solution
Antiglaucoma
Approved uses
Open-angle glaucoma or ocular hypertension
One drop in the conjunctival sac of the affected eye(s) once daily in the evening; not to exceed once daily.
About 35% hold a 25% or greater IOP reduction, maintained through 12 months.
Contraindications
None.
0.024% (0.24 mg/mL) ophthalmic solution, 2.5 mL fill in a 4 mL container, 5 mL fill in a 7.5 mL container
Prostaglandin analog thought to lower intraocular pressure by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. In the eye it is rapidly metabolized to latanoprost acid (active moiety) and butanediol mononitrate, which is metabolized to 1,4-butanediol and nitric oxide. IOP reduction starts approximately 1 to 3 hours after the first administration, with the maximum effect reached after 11 to 13 hours in eyes with elevated intraocular pressure.
Warnings & Precautions
- Iris pigmentation: It is expected to increase as long as VYZULTA is administered, from increased melanin content rather than more melanocytes, and is likely to be permanent after discontinuation. Typically, brown pigmentation around the pupil spreads concentrically towards the periphery of the iris; neither nevi nor freckles appear to be affected. Patients with noticeably increased pigmentation can continue treatment but should be examined regularly. The long-term effects of increased pigmentation are not known.
- Periorbital pigmentation: Eyelid tissue darkening is likely reversible in most patients after discontinuation, unlike the iris change.
- Eyelash changes: VYZULTA may gradually change eyelashes and vellus hair in the treated eye, including increased length, thickness, and number of lashes or hairs, usually reversible upon discontinuation. These changes may result in a disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth.
- Intraocular inflammation: Caution with a history of iritis or uveitis, and generally not for use with active intraocular inflammation, which may be exacerbated.
- Macular edema: Macular edema including cystoid macular edema has been reported with prostaglandin analogs; caution in aphakia, in pseudophakia with a torn posterior lens capsule, and with other known risk factors.
- Bacterial keratitis: Reported with inadvertently contaminated multiple-dose containers, in most cases in patients with concurrent corneal disease or a disrupted ocular epithelial surface.
- Use with contact lens: Contact lenses should be removed prior to administration because this product contains benzalkonium chloride 0.2 mg/mL; lenses may be reinserted 15 minutes after administration.
Common Side Effects
- Ocular, 2% or more: conjunctival hyperemia 6%, eye irritation 4%, eye pain 3%, instillation site pain 2% (811 patients in 2 controlled trials of up to 12 months).
- Discontinuation: about 0.6% stopped for ocular reactions including ocular hyperemia, conjunctival irritation, eye irritation, eye pain, conjunctival edema, blurred vision, punctate keratitis, and foreign body sensation.
- Ocular, pigment and lash changes: increased iris and periorbital (eyelid) pigmentation, and increased eyelash and vellus hair length, thickness, and number in the treated eye.
- Ocular, serious: intraocular inflammation (iritis/uveitis), macular edema including cystoid macular edema, and bacterial keratitis associated with contaminated multiple-dose containers.
Pregnancy: No available human data. IV dosing in pregnant rabbits during organogenesis was abortifacient and teratogenic at exposures 0.28 times the clinical dose and above, with 100% embryofetal lethality at 23 times and malformations including aortic coarctation, domed head, sternebral and vertebral anomalies, and limb hyperextension; not teratogenic in rats at 87 times the clinical dose, with embryofetal lethality and anomalies at 174 times.
Lactation: No data on presence in human milk, effects on the breastfed infant, or effects on milk production.
Not recommended at 16 years of age and younger because of pigmentation risk with long-term chronic use.